TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PATADAY ONCE DAILY RELIEF

OLOPATADINE HYDROCHLORIDE
Approved 2004-12-22
4
Indications
--
Phase 3 Trials
1
Priority Reviews
21
Years on Market

Details

Status
Over-the-counter
First Approved
2004-12-22
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: OLOPATADINE HYDROCHLORIDE

PATADAY ONCE DAILY RELIEF Approval History

Loading approval history...

What PATADAY ONCE DAILY RELIEF Treats

4 FDA approvals

Originally approved for its first indication in 2004 . Covers 4 distinct patient populations.

  • Other (4)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PATADAY ONCE DAILY RELIEF FDA Label Details

Pro

PATADAY ONCE DAILY RELIEF Patents & Exclusivity

Latest Patent: May 2032

Patents (2 active)

US8791154 Expires May 19, 2032
US9533053 Expires May 19, 2032
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.